# Buspirone Treatment of Anxiety in Williams Syndrome

> **NCT04807517** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 20 (actual)

## Conditions studied

- Williams Syndrome
- Anxiety

## Interventions

- **DRUG:** Buspirone

## Key facts

- **NCT ID:** NCT04807517
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-01
- **Primary completion:** 2023-09-11
- **Final completion:** 2023-09-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04807517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04807517, "Buspirone Treatment of Anxiety in Williams Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04807517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*